5-Tert-butyl-1-propan-2-ylimidazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-Tert-butyl-1-propan-2-ylimidazole
• 英文别名: 5-tert-butyl-1-propan-2-ylimidazole
• 化学式: C₁₀H₁₈N₂
• 分子量: 166.26
• InChiKey: GQWNWQKZWHTRAE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE
  申请人：SHANGHAI RINGENE BIOPHARMA CO., LTD.

  公开号：US20220127271A1

  公开（公告）日：2022-04-28

  Disclosed are a nitrogen-containing fused heterocyclic SHP2 inhibitor compound, a preparation method, and use. The nitrogen-containing fused heterocyclic SHP2 inhibitor compound is represented by formula I below. The compound has high inhibitory activity for an SHP2 enzyme and tumor cell proliferation, and has good druggability.

  揭示了一种含氮的融合杂环SHP2抑制剂化合物，以及其制备方法和用途。该含氮的融合杂环SHP2抑制剂化合物由下面的化学式I表示。该化合物对SHP2酶和肿瘤细胞增殖具有高抑制活性，并具有良好的药物可用性。
• Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
  申请人：THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH

  公开号：US10961200B2

  公开（公告）日：2021-03-30

  Provided is a compound of formula (I) in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.

  提供了一种式 (I) 的化合物 其中 Ar1、R1、U、V、W、X 和 p 如本文所述。还提供了使用式（I）化合物的方法，包括治疗癌症的方法、治疗对抗癌剂有抗药性的癌细胞患者的方法，以及抑制细胞中乳酸脱氢酶 A（LDHA）和/或乳酸脱氢酶 B（LDHB）活性的方法。
• Heterocyclic derivatives useful as SHP2 inhibitors
  申请人：Jacobio Pharmaceuticals Co., Ltd.

  公开号：US10988466B2

  公开（公告）日：2021-04-27

  This invention relates to certain novel pyrazine derivatives (Formula I) as SHP2 inhibitors which is shown as formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, this invention is directed to fused heterocyclic group derivatives useful as inhibitors of SHP2, methods for producing such compounds and methods for treating a SHP2-mediated disorder.

  本发明涉及作为 SHP2 抑制剂的某些新型吡嗪衍生物（式 I）（如式 I 所示）、其合成及其用于治疗 SHP2 介导的疾病。更具体地说，本发明涉及作为 SHP2 抑制剂的融合杂环基团衍生物、生产此类化合物的方法以及治疗 SHP2 介导的疾病的方法。
• NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS
  申请人：Jacobio Pharmaceuticals Co., Ltd.

  公开号：US20200392128A1

  公开（公告）日：2020-12-17

  This invention relates to certain novel pyrazine derivatives (Formula I) as SHP2 inhibitors which is shown as formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, this invention is directed to fused heterocyclic group derivatives useful as inhibitors of SHP2, methods for producing such compounds and methods for treating a SHP2-mediated disorder.
• [EN] PLACENTAL DERIVED NATURAL KILLER CELLS FOR TREATMENT OF CORONAVIRUS INFECTIONS<br/>[FR] CELLULES TUEUSES NATURELLES DÉRIVÉES DU PLACENTA POUR LE TRAITEMENT D'INFECTIONS À CORONAVIRUS
  申请人：CELULARITY INC

  公开号：WO2021155312A1

  公开（公告）日：2021-08-05

  Provided herein are methods of using populations of natural killer (NK) cells and/or ILC3 cells derived from a population of hematopoietic stem or progenitor cells in methods for treating a viral infection, e.g., a coronavirus infection.